Cargando…

Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study

INTRODUCTION: Fabry disease (FD) is a lysosomal storage disorder leading to decreased α-galactosidase A enzyme activity and subsequent abnormal accumulation of glycosphingolipids in various organs. Although histological evidence of lung involvement has been demonstrated, the functional impact of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franzen, Daniel P., Nowak, Albina, Haile, Sarah R., Mottet, Dominique, Bonani, Marco, Dormond, Olivier, Kohler, Malcolm, Krayenbuehl, Pierre A., Barbey, Frederic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526574/ https://www.ncbi.nlm.nih.gov/pubmed/28742806 http://dx.doi.org/10.1371/journal.pone.0180437

Ejemplares similares

Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease
por: Gatterer, Constantin, et al.
Publicado: (2023)

Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
por: Franzen, Daniel, et al.
Publicado: (2018)

Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study
por: Nowak, Albina, et al.
Publicado: (2018)

Fabry nephropathy: 5 years of enzyme replacement therapy—a short review
por: Barbey, Frédéric, et al.
Publicado: (2008)

COVID-19 in Fabry disease: a reference center prospective study
por: Bothou, Christina, et al.
Publicado: (2022)

Prevalence and Risk Factors of Sleep Disordered Breathing in Fabry disease: A Prospective Cohort Study
por: Franzen, Daniel, et al.
Publicado: (2015)

Endocrine disorders in patients with Fabry disease: insights from a reference centre prospective study
por: Bothou, Christina, et al.
Publicado: (2021)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
por: Nowak, Albina, et al.
Publicado: (2022)

Neuropsychiatric Symptoms and Their Association With Sex, Age, and Enzyme Replacement Therapy in Fabry Disease: A Systematic Review
por: Mroczek, Magdalena, et al.
Publicado: (2022)

Detection of single nucleotide and copy number variants in the Fabry disease-associated GLA gene using nanopore sequencing
por: Nowak, Albina, et al.
Publicado: (2021)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Globotrioasylsphingosine Levels and Optical Coherence Tomography Angiography in Fabry Disease Patients
por: Wiest, Maximilian Robert Justus, et al.
Publicado: (2021)

Relationship of Vessel Density to Vessel Length Density in Patients with Treated Fabry Disease
por: Wiest, Maximilian Robert Justus, et al.
Publicado: (2023)

Aortic arch stiffness in Fabry disease
por: Bensalah, Zoubir M, et al.
Publicado: (2013)

Semen and male genital tract characteristics of patients with Fabry disease: the FERTIFABRY multicentre observational study
por: Papaxanthos-Roche, Aline, et al.
Publicado: (2019)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Continuous Cardiac Troponin I Release in Fabry Disease
por: Feustel, Andreas, et al.
Publicado: (2014)

Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial
por: Nowak, Albina, et al.
Publicado: (2016)

Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up
por: Carnicer-Cáceres, Clara, et al.
Publicado: (2021)

Podocyturia in Fabry disease: a 10-year follow-up
por: Vujkovac, Bojan, et al.
Publicado: (2021)

Persistent increase in cardiac troponin I in Fabry disease: a case report
por: Tanislav, Christian, et al.
Publicado: (2011)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Determinants of outcome of solitary fibrous tumors of the pleura: an observational cohort study
por: Franzen, Daniel, et al.
Publicado: (2014)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Cardiac device implantation in Fabry disease: A retrospective monocentric study
por: Sené, Thomas, et al.
Publicado: (2016)

Follow-up of Cardiac Fabry Disease Treated by Cardiac Resynchronization Therapy
por: Fukuda, Yuko, et al.
Publicado: (2017)

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts
por: Germain, Dominique P., et al.
Publicado: (2019)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Fabry Disease – Underestimated in the Differential Diagnosis of Multiple Sclerosis?
por: Böttcher, Tobias, et al.
Publicado: (2013)

Fabry disease in the Spanish population: observational study with detection of 77 patients
por: Vieitez, Irene, et al.
Publicado: (2018)

Balance control impairments in Fabry disease
por: Peultier-Celli, Laetitia, et al.
Publicado: (2022)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation
por: Pollmann, Solvey, et al.
Publicado: (2021)

Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease
por: Mauhin, Wladimir, et al.
Publicado: (2019)

Lipid profile in adult patients with Fabry disease - Ten-year follow up
por: Stepien, Karolina M., et al.
Publicado: (2017)

Cognitive functioning and depressive symptoms in Fabry disease: A follow‐up study
por: Körver, Simon, et al.
Publicado: (2020)

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
por: Ortiz, Alberto, et al.
Publicado: (2016)

Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire
por: Noël, Esther, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c6g4rus09b6i4ninhcfpbdm7v6